1. This is the Explanatory Statement to the Statement of Principles concerning bronchiectasis (Reasonable Hypothesis) (No. 30 of 2017).

**Background**

2. The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), revokes Instrument No. 17 of 2009, determined under subsection 196B(2) of the VEA concerning bronchiectasis.

3. The Authority is of the view that there is sound medical-scientific evidence that indicates that bronchiectasis and death from bronchiectasis can be related to particular kinds of service. The Authority has therefore determined pursuant to subsection 196B(2) of the VEA a Statement of Principles concerning bronchiectasis (Reasonable Hypothesis) (No. 30 of 2017). This Instrument will in effect replace the revoked Statement of Principles.

**Purpose and Operation**

4. The Statement of Principles will be applied in determining claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

5. The Statement of Principles sets out the factors that must as a minimum exist, and which of those factors must be related to the following kinds of service rendered by a person:

- operational service under the VEA;
- peacekeeping service under the VEA;
- hazardous service under the VEA;
- British nuclear test defence service under the VEA;
- warlike service under the MRCA;
- non-warlike service under the MRCA,

before it can be said that a reasonable hypothesis has been raised connecting bronchiectasis or death from bronchiectasis, with the circumstances of that service. The Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

6. This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 6 September 2016 concerning bronchiectasis in accordance with section 196G of the VEA. The investigation involved an examination
7. The contents of this Instrument are in similar terms as the revoked Instrument. Comparing this Instrument and the revoked Instrument, the differences include:

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'bronchiectasis' in subsection 7(2);
- revising the factor in subsection 9(1) concerning 'viral or bacterial pneumonia';
- new factors in subsections 9(2) & 9(24) concerning 'pertussis';
- revising the factors in subsections 9(5) & 9(27) concerning 'bronchial obstruction', by the inclusion of a note;
- revising the factors in subsections 9(6) & 9(28) concerning 'vapours, gases or fumes of a chemical agent';
- new factors in subsections 9(7) & 9(29) concerning 'occupational lung disease';
- revising the factors in subsections 9(8) & 9(30) concerning 'sulphur mustard (mustard gas)';
- revising the factors in subsections 9(9) & 9(31) concerning 'aspiration pneumonitis';
- revising the factors in subsections 9(10) & 9(32) concerning 'gastro-oesophageal reflux disease, with erosive oesophagitis or oesophageal stricture';
- revising the factors in subsections 9(11) & 9(33) concerning 'allergic bronchopulmonary aspergillosis', by the inclusion of a note;
- revising the factors in subsections 9(12) & 9(34) concerning 'solid organ or bone marrow transplantation';
- revising the factors in subsections 9(13) & 9(35) concerning 'fibrosis or fibrosing interstitial lung disease';
- revising the factors in subsections 9(14) & 9(36) concerning 'arsenic', by the inclusion of a note;
- new factors in subsections 9(15) & 9(37) concerning 'connective tissue diseases';
- new factors in subsections 9(16) & 9(38) concerning 'human immunodeficiency virus';
- new factors in subsections 9(17) & 9(39) concerning 'haematological malignancy';
- new factors in subsections 9(18) & 9(40) concerning 'immunosuppressive drug';
- new factors in subsections 9(19) & 9(41) concerning 'human T-cell lymphotrophic virus type 1';
- new factors in subsections 9(20) & 9(42) concerning 'inflammatory bowel disease';
- new factors in subsections 9(21) & 9(43) concerning 'severe and persistent asthma';
- new factors in subsections 9(22) & 9(44) concerning 'chronic obstructive pulmonary disease';
- revising the factor in subsection 9(23) concerning 'acute viral or bacterial lower respiratory tract infection';
- new definitions of 'immunosuppressive drug', 'MRCA', 'severe and persistent asthma', 'specified list of chemical agents', 'specified list of connective tissue
diseases', 'specified list of occupational lung diseases' and 'VEA' in Schedule 1 - Dictionary;

- revising the definitions of 'allergic bronchopulmonary aspergillosis', 'aspiration pneumonitis', 'being exposed to arsenic as specified', 'bronchial obstruction' and 'relevant service' in Schedule 1 - Dictionary; and

- deleting the definitions of 'inhaling toxic gases or fumes' and 'pneumonia'.

Consultation

8. Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to bronchiectasis in the Government Notices Gazette of 6 September 2016, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants. The Authority invited submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field. One submission was received for consideration by the Authority during the investigation.

Human Rights

9. This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011. A Statement of Compatibility with Human Rights follows.

Finalisation of Investigation


References

11. A list of references relating to the above condition is available to any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA. Any such request must be made in writing to the Repatriation Medical Authority at the following address:

   The Registrar
   Repatriation Medical Authority
   GPO Box 1014
   BRISBANE QLD 4001
Statement of Compatibility with Human Rights
(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

Instrument No.: Statement of Principles No. 30 of 2017
Kind of Injury, Disease or Death: Bronchiectasis

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA). Part XIA of the VEA requires the determination of these instruments outlining the factors linking particular kinds of injury, disease or death with service such being determined solely on the available sound medical-scientific evidence.

2. This Legislative Instrument:
   - facilitates claimants in making, and the Repatriation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have bronchiectasis;
   - facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
   - outlines the factors which the current sound medical-scientific evidence indicates must as a minimum exist, before it can be said that a reasonable hypothesis has been raised, connecting bronchiectasis with the circumstances of eligible service rendered by a person, as set out in clause 5 of the Explanatory Statement;
   - replaces Instrument No. 17 of 2009; and
   - reflects developments in the available sound medical-scientific evidence concerning bronchiectasis which have occurred since that earlier instrument was determined.

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA.
Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

- the right to social security (Art 9, *International Covenant on Economic, Social and Cultural Rights*; Art 26, *Convention on the Rights of the Child* and Art 28, *Convention on the Rights of Persons with Disabilities*) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'\(^1\);

- the right to an adequate standard of living (Art 11, ICSECR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;

- the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICSECR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members;

- the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD); and

- ensuring that those rights "will be exercised without discrimination of any kind as to race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status" (Art 2, ICESCR).

**Conclusion**

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

Repatriation Medical Authority

---

\(^1\) In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.